Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
Exact Sciences (NASDAQ: EXAS) will present 10 abstracts at the 2024 San Antonio Breast Cancer Symposium, showcasing their Precision Oncology portfolio. The presentations focus on the Oncotype DX Breast Recurrence Score® test, highlighting its effectiveness in guiding chemotherapy decisions and managing treatment costs.
New research from Japan demonstrates the test's cost-effectiveness, while other studies reveal that African American women typically show higher Recurrence Score® results compared to non-Hispanic White women, though with similar survival outcomes. The company aims to improve breast cancer care through personalized treatment planning and innovative solutions across all stages of cancer care.
Exact Sciences (NASDAQ: EXAS) presenterà 10 abstract al 2024 San Antonio Breast Cancer Symposium, mettendo in evidenza il loro portafoglio di Oncologia di Precisione. Le presentazioni si concentrano sul test Oncotype DX Breast Recurrence Score®, evidenziando la sua efficacia nel guidare le decisioni riguardanti la chemioterapia e nella gestione dei costi di trattamento.
Nuove ricerche dal Giappone dimostrano il costo-efficacia del test, mentre altri studi rivelano che le donne afroamericane mostrano tipicamente risultati più elevati nel punteggio di Recurrence Score® rispetto alle donne bianche non ispaniche, sebbene con esiti di sopravvivenza simili. L'azienda punta a migliorare le cure per il cancro al seno attraverso una pianificazione del trattamento personalizzata e soluzioni innovative in tutte le fasi dell'assistenza oncologica.
Exact Sciences (NASDAQ: EXAS) presentará 10 resúmenes en el Simposio de Cáncer de Mama de San Antonio 2024, exhibiendo su portafolio de Oncología de Precisión. Las presentaciones se enfocan en el test Oncotype DX Breast Recurrence Score®, subrayando su efectividad para guiar decisiones sobre quimioterapia y gestionar los costos de tratamiento.
Nueva investigación de Japón demuestra la rentabilidad del test, mientras que otros estudios revelan que las mujeres afroamericanas típicamente muestran resultados más altos en el Recurrence Score® en comparación con las mujeres blancas no hispanas, aunque con resultados de supervivencia similares. La compañía tiene como objetivo mejorar los cuidados del cáncer de mama a través de una planificación de tratamiento personalizada y soluciones innovadoras en todas las etapas del cuidado del cáncer.
엑자트 사이언스 (NASDAQ: EXAS)는 2024년 샌안토니오 유방암 심포지엄에서 10개의 초록을 발표하며 그들의 정밀 종양학 포트폴리오를 선보입니다. 발표는 온코타입 DX 유방재발점수® 테스트에 초점을 맞추며, 이는 화학요법 결정과 치료 비용 관리를 안내하는 데 효과적임을 강조합니다.
일본의 새로운 연구는 이 테스트의 비용 효율성을 입증하며, 다른 연구들은 아프리카계 미국인 여성들이 비히스패닉 백인 여성들에 비해 일반적으로 더 높은 재발 점수® 결과를 보인다는 것을 밝혀냈지만, 생존 결과는 유사하다는 것을 보여줍니다. 이 회사는 모든 암 치료 단계에서 개인화된 치료 계획과 혁신적인 솔루션을 통해 유방암 치료를 개선하는 것을 목표로 하고 있습니다.
Exact Sciences (NASDAQ: EXAS) présentera 10 résumés au Symposium sur le cancer du sein de San Antonio 2024, mettant en avant leur portefeuille d'Oncologie de Précision. Les présentations se concentrent sur le test Oncotype DX Breast Recurrence Score®, soulignant son efficacité à guider les décisions de chimiothérapie et à gérer les coûts de traitement.
De nouvelles recherches provenant du Japon démontrent la rentabilité de ce test, tandis que d'autres études révèlent que les femmes afro-américaines présentent généralement des résultats de Recurrence Score® plus élevés par rapport aux femmes blanches non hispaniques, bien que les taux de survie soient similaires. L'entreprise vise à améliorer les soins du cancer du sein grâce à une planification de traitement personnalisée et à des solutions innovantes à tous les stades de la prise en charge du cancer.
Exact Sciences (NASDAQ: EXAS) wird auf dem San Antonio Breast Cancer Symposium 2024 10 Abstracts präsentieren, in denen das Portfolio der Präzisionsonkologie hervorgehoben wird. Die Präsentationen konzentrieren sich auf den Oncotype DX Breast Recurrence Score® Test und betonen dessen Wirksamkeit bei der Entscheidungsfindung für Chemotherapie und der Kostenmanagementbehandlung.
Neue Forschung aus Japan zeigt die Kostenwirksamkeit des Tests, während andere Studien offenbaren, dass afroamerikanische Frauen typischerweise höhere Ergebnisse im Recurrence Score® im Vergleich zu nicht-hispanischen weißen Frauen zeigen, jedoch mit ähnlichen Überlebensraten. Das Unternehmen hat sich zum Ziel gesetzt, die Pflege von Brustkrebs durch personalisierte Behandlungsplanung und innovative Lösungen in allen Phasen der Krebsbehandlung zu verbessern.
- Presentation of 10 research abstracts demonstrating portfolio strength
- Evidence of Oncotype DX test's effectiveness in treatment decision-making
- Data showing test's potential for cost management in Japanese market
- Expansion of precision oncology capabilities across different cancer care stages
- None.
Insights
The new research data presented at SABCS 2024 reinforces the clinical utility and cost-effectiveness of Exact Sciences' Oncotype DX Breast Recurrence Score test. Key findings demonstrate how the test helps optimize chemotherapy decisions and manage treatment costs in Japan, while also revealing important insights about racial disparities in test results between African American and non-Hispanic White women.
The breadth of research spans important areas including:
- Treatment guidance in metastatic breast cancer
- Cost-effectiveness analysis in the Japanese healthcare system
- Genomic risk assessment during pregnancy
- Molecular profiling across different patient demographics
Most notably, the studies validate the test's role in personalizing treatment decisions and potentially reducing unnecessary chemotherapy use. The expansion into molecular residual disease monitoring signals Exact Sciences' strategic move to cover the complete cancer care continuum.
New data supports the value of the Oncotype DX Breast Recurrence Score® test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer patients globally
“Exact Sciences is committed to improving breast cancer care by providing actionable insights that support informed treatment decisions and help achieve the best outcomes for patients across all backgrounds,” said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology at Exact Sciences. “For 20 years, the Oncotype DX test has led the way in personalized treatment planning, and the new findings presented at SABCS reinforce its trusted role among clinicians, research institutions, and patients alike. With the addition of our OncoExTra® test and our anticipated molecular residual disease monitoring test, we’re equipping clinicians with innovative solutions to support patient needs throughout every stage of cancer care.”
In collaboration with leading breast cancer experts and research groups, Exact Sciences will share data highlighting how the Oncotype DX test helps guide effective chemotherapy use in everyday practice and clinical trials. New findings from
Data presentations across Exact Sciences’ Precision Oncology portfolio include:
Title: (Neo)adjuvant nab-PAC weekly vs sb-PAC q2w, followed by EC q2w, in genomically or clinically high-risk HR+/HER- early breast cancer according to ET-response: Final survival results from the WSG ADAPT-HR+/HER2- chemotherapy-trial
Session: Late breaking oral presentation GS3-04. Friday, December 13, 9:00-11:45 AM CST; General Session 3, Hall 1
Title: Correlation between the Oncotype DX Recurrence Score® categories and progression-free survival of patients with primary metastatic estrogen-receptor positive and HER2-negative breast cancer
Session: Poster P4-12-01. Thursday, December 12, 5:30-7:00 PM CST; Poster Session 4, Halls 2 and 3
Title: The Oncotype DX® test to guide adjuvant chemotherapy treatment decisions for early node-negative HR+/HER2- breast cancer patients in
Session: Poster P4-11-07. December 12, 5:30-7:00 PM CST; Poster Session 4, Halls 2 and 3
Title: Comparative analysis of the Oncotype DX Breast Recurrence Score® assay for neoadjuvant letrozole/abemaciclib versus chemotherapy in Stage II-III, Ki67≥
Session: Poster P1-09-12. Wednesday, December 11, 12:30-2:00 PM CST; Poster Session 1, Halls 2 and 3
Title: Genomic risk score distribution and outcomes of patients with early-stage breast cancer diagnosed during pregnancy
Session: Poster P1-03-30. Wednesday, December 11, 12:30-2:00 PM CST; Poster Session 1, Halls 2 and 3
Title: Oncotype DX Breast Recurrence Score® distribution and prognostic value according to prior pregnancy status in young women with breast cancer
Session: Poster P1-01-23. Wednesday, December 11, 12:30 – 2:00 PM CST; Poster Session 1, Halls 2 and 3
Title: Oncotype DX assay association with breast cancer outcomes in different racial and ethnic groups: a retrospective analysis
Session: Poster P2-07-06. Wednesday, December 11, 5:30-7:00 PM CST; Poster Session 2, Halls 2 and 3
Title: Actionable gene alterations affecting the PI3K/AKT and MAPK signaling pathways in breast cancer
Session: Poster P4-03-25. Thursday, December 12, 5:30-7:00 PM CST; Poster Session 4, Halls 2 and 3
Title: Molecular landscape of breast cancer in pre- and postmenopausal women
Session: Poster P3-03-30. Thursday, December 12, 12:00-2:00 PM CST; Poster Session 3, Section Row 3 & Poster 30
Title: Economic analysis of germline genetic testing to assess for hereditary breast cancer: a systematic review
Session: Poster P4-04-14. Thursday, December 12, 5:30-7:00 PM CST; Poster Session 4, Halls 2 and 3
About Exact Sciences’ Precision Oncology portfolio
Exact Sciences’ Precision Oncology portfolio delivers actionable genomic insights to inform prognosis and cancer treatment after a diagnosis. In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. The Oncotype DX test is recognized as the standard of care and is included in all major breast cancer treatment guidelines. The OncoExTra test applies comprehensive tumor profiling, utilizing whole exome and whole transcriptome sequencing, to aid in therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. With an extensive panel of approximately 20,000 genes and 169 introns, the OncoExTra test is one of the most comprehensive genomic (DNA) and transcriptomic (RNA) panels available today. The Riskguard® hereditary cancer test provides an individualized patient report that includes gene-specific and familial risks using a simple blood or saliva sample for 10 common cancers: colorectal, breast, prostate, skin, ovarian, endometrial, pancreatic, gastric, kidney, and endocrine. Exact Sciences enables patients to take a more active role in their cancer care and makes it easy for providers to order tests, interpret results, and personalize medicine.
To learn more, visit precisiononcology.exactsciences.com.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
NOTE: Oncotype, Oncotype DX Breast Recurrence Score, Breast Recurrence Score, Recurrence Score, and OncoExTra are registered trademarks of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences. Exact Sciences, Cologuard and Riskguard are registered trademarks of Exact Sciences Corporation. Cologuard, Riskguard, and OncoExTra are only available in
Forward-Looking Statement
This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated.
Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements regarding our expectations for the commercialization of the Cologuard Plus test and the performance of the Cologuard Plus test in a commercial setting. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241125084124/en/
Media (US)
Lisa Warshaw
lwarshaw@exactsciences.com
Media (OUS)
Federico Maiardi
+41 79-138-1326
fmaiardi@exactsciences.com
Investors
Erik Holznecht
+1 608-800-6605
investors@exactsciences.com
Source: Exact Sciences Corp.
FAQ
What will Exact Sciences (EXAS) present at SABCS 2024?
How does the Oncotype DX test affect treatment costs according to new Japanese data?
What did Exact Sciences (EXAS) research reveal about racial differences in test results?
